SRT1720, a Sirt1 activator, has been shown to decrease p65 acetylation, promote autophagic processes in high glucose-induced podocyte EMT, alleviate renal fibrosis, and restore kidney function (172). Here, SIRT1 is linked to renal fibrosis.